BT-474:修订间差异

维基百科,自由的百科全书
删除的内容 添加的内容
:​ // Edit via Wikiplus
內容擴充
第1行: 第1行:
'''BT-474''' (亦稱'''ATCC HTB-20''') 是[[人類]]高度[[非整倍體]]乳腺導管癌{{le|細胞系|Immortalised cell line}}<ref>{{cite journal |last1=Lasfargues |first1=EY |last2=Coutinho |first2=WG |last3=Dion |first3=AS |title=A human breast tumor cell line (BT-474) that supports mouse mammary tumor virus replication. |journal=In vitro |date=1979-09 |volume=15 |issue=9 |pages=723-9 |doi=10.1007/bf02618252 |pmid=94035 |url=https://www.ncbi.nlm.nih.gov/m/pubmed/94035/ |accessdate=2019-12-07}}</ref>,最初分離自一位60歲的[[白人]][[女性]][[乳腺]]浸潤性導管癌[[患者]]。BT-474細胞包含着許多具有典型凋亡細胞形態的細胞,已知細胞不存在參與凋亡誘導的[[p53|p53蛋白]],而抑制細胞凋亡的{{le|Bcl-2|Bcl-2}}則以中等水平表達。BT-474細胞傾向轉移到局部[[淋巴結]],並且能夠在[[肺]]部形成微轉移病變<ref>{{cite journal |last1=van Slooten |first1=HJ |last2=Bonsing |first2=BA |last3=Hiller |first3=AJ |last4=Colbern |first4=GT |last5=van Dierendonck |first5=JH |last6=Cornelisse |first6=CJ |last7=Smith |first7=HS |title=Outgrowth of BT-474 human breast cancer cells in immune-deficient mice: a new in vivo model for hormone-dependent breast cancer. |journal=British journal of cancer |date=1995-07 |volume=72 |issue=1 |pages=22-30 |doi=10.1038/bjc.1995.271 |pmid=7599056 |url=https://www.ncbi.nlm.nih.gov/m/pubmed/7599056/ |accessdate=2019-12-07}}</ref>。BT-474有55個[[染色體]],並且具有極其複雜的[[基因組]]序列,大多數染色體計數在[[染色體倍性|超四倍體]]的範圍內,同時又缺失三個[[染色體]](N11、N13和N22),並且某些染色體(N9、N14和N15)存在着低於適當[[比例]]的問題<ref name=a>{{cite journal |last1=Ciotlos |first1=S |last2=Mao |first2=Q |last3=Zhang |first3=RY |last4=Li |first4=Z |last5=Chin |first5=R |last6=Gulbahce |first6=N |last7=Liu |first7=SJ |last8=Drmanac |first8=R |last9=Peters |first9=BA |title=Whole genome sequence analysis of BT-474 using complete Genomics' standard and long fragment read technologies. |journal=GigaScience |date=2016 |volume=5 |pages=8 |doi=10.1186/s13742-016-0113-x |pmid=26865974 |url=https://www.ncbi.nlm.nih.gov/m/pubmed/26865974/ |accessdate=2019-12-07}}</ref>。經過吉姆薩[[胰蛋白酶]]帶的測試後,未顯示出有明顯的[[海拉細胞|HeLa]]標記物,並且在[[放射免疫分析]]中,沒有檢測到α-[[乳清蛋白]]的產生,但是發現BT-483細胞高度表達着[[孕酮受體]]<ref>{{cite journal |last1=Lasfargues |first1=EY |last2=Coutinho |first2=WG |last3=Redfield |first3=ES |title=Isolation of two human tumor epithelial cell lines from solid breast carcinomas. |journal=Journal of the National Cancer Institute |date=1978-10 |volume=61 |issue=4 |pages=967-78 |pmid=212572 |url=https://www.ncbi.nlm.nih.gov/m/pubmed/212572/ |accessdate=2019-12-07}}</ref>。BT-474應用於研究癌症生物學和開發新[[藥物]]<ref name=a/>。
{{Multiple issues|
{{Expert|subject=医学|time=2019-12-07T09:42:23+00:00}}
{{Refimprove|time=2019-12-07T09:42:23+00:00}}
}}
'''BT-474''' (亦稱'''ATCC HTB-20''') 是[[人類]]乳腺導管癌{{le|細胞系|Immortalised cell line}}<ref>{{cite journal |last1=Lasfargues |first1=EY |last2=Coutinho |first2=WG |last3=Dion |first3=AS |title=A human breast tumor cell line (BT-474) that supports mouse mammary tumor virus replication. |journal=In vitro |date=1979-09 |volume=15 |issue=9 |pages=723-9 |doi=10.1007/bf02618252 |pmid=94035 |url=https://www.ncbi.nlm.nih.gov/m/pubmed/94035/ |accessdate=2019-12-07}}</ref>,最初分離自一位60歲的[[白人]][[女性]][[乳腺]]浸潤性導管癌[[患者]]。BT-474有55個[[染色體]],大多數染色體計數在[[染色體倍性|超四倍體]]的範圍內,同時又缺失三個[[染色體]](N11、N13和N22),並且某些染色體(N9、N14和N15)存在着低於適當[[比例]]的問題。經過吉姆薩[[胰蛋白酶]]帶的測試後,未顯示出有明顯的[[海拉細胞|HeLa]]標記物,並且在[[放射免疫分析]]中,沒有檢測到α-[[乳清蛋白]]的產生,但是發現BT-483細胞高度表達着[[孕酮受體]]<ref>{{cite journal |last1=Lasfargues |first1=EY |last2=Coutinho |first2=WG |last3=Redfield |first3=ES |title=Isolation of two human tumor epithelial cell lines from solid breast carcinomas. |journal=Journal of the National Cancer Institute |date=1978-10 |volume=61 |issue=4 |pages=967-78 |pmid=212572 |url=https://www.ncbi.nlm.nih.gov/m/pubmed/212572/ |accessdate=2019-12-07}}</ref>。


== 參考資料 ==
== 參考資料 ==

2019年12月7日 (六) 10:32的版本

BT-474 (亦稱ATCC HTB-20) 是人類高度非整倍體乳腺導管癌細胞系[1],最初分離自一位60歲的白人女性乳腺浸潤性導管癌患者。BT-474細胞包含着許多具有典型凋亡細胞形態的細胞,已知細胞不存在參與凋亡誘導的p53蛋白,而抑制細胞凋亡的Bcl-2英语Bcl-2則以中等水平表達。BT-474細胞傾向轉移到局部淋巴結,並且能夠在部形成微轉移病變[2]。BT-474有55個染色體,並且具有極其複雜的基因組序列,大多數染色體計數在超四倍體的範圍內,同時又缺失三個染色體(N11、N13和N22),並且某些染色體(N9、N14和N15)存在着低於適當比例的問題[3]。經過吉姆薩胰蛋白酶帶的測試後,未顯示出有明顯的HeLa標記物,並且在放射免疫分析中,沒有檢測到α-乳清蛋白的產生,但是發現BT-483細胞高度表達着孕酮受體[4]。BT-474應用於研究癌症生物學和開發新藥物[3]

參考資料

  1. ^ Lasfargues, EY; Coutinho, WG; Dion, AS. A human breast tumor cell line (BT-474) that supports mouse mammary tumor virus replication.. In vitro. 1979-09, 15 (9): 723–9 [2019-12-07]. PMID 94035. doi:10.1007/bf02618252. 
  2. ^ van Slooten, HJ; Bonsing, BA; Hiller, AJ; Colbern, GT; van Dierendonck, JH; Cornelisse, CJ; Smith, HS. Outgrowth of BT-474 human breast cancer cells in immune-deficient mice: a new in vivo model for hormone-dependent breast cancer.. British journal of cancer. 1995-07, 72 (1): 22–30 [2019-12-07]. PMID 7599056. doi:10.1038/bjc.1995.271. 
  3. ^ 3.0 3.1 Ciotlos, S; Mao, Q; Zhang, RY; Li, Z; Chin, R; Gulbahce, N; Liu, SJ; Drmanac, R; Peters, BA. Whole genome sequence analysis of BT-474 using complete Genomics' standard and long fragment read technologies.. GigaScience. 2016, 5: 8 [2019-12-07]. PMID 26865974. doi:10.1186/s13742-016-0113-x. 
  4. ^ Lasfargues, EY; Coutinho, WG; Redfield, ES. Isolation of two human tumor epithelial cell lines from solid breast carcinomas.. Journal of the National Cancer Institute. 1978-10, 61 (4): 967–78 [2019-12-07]. PMID 212572. 

外部連結